Singular Genomics Expands Its G4X™ Initiative with Beth Israel Deaconess Medical Center

Expansion of G4X™ Initiative by Singular Genomics

Introduction
In an exciting development reported on March 12, 2026, Singular Genomics has named the Spatial Technologies Unit (STU) at Beth Israel Deaconess Medical Center (BIDMC) as a G4X™ Center of Excellence. This prestigious designation is a significant step in advancing the use of G4X™ technologies, which are poised to revolutionize research in spatial profiling.

The Role of the Spatial Technologies Unit
The STU operates as a key resource within BIDMC and the Dana-Farber/Harvard Cancer Center (DF/HCC). It offers vital support for researchers engaged in a range of studies, including spatial tissue profiling and single-cell analysis. Their work spans across basic research, translational science, and clinical trials, demonstrating the unit’s versatile approach to scientific inquiry.

By becoming a G4X Center of Excellence, the STU will collaborate intensively with Singular Genomics to help researchers efficiently conduct large-scale G4X™ studies. This partnership is designed to disseminate best practices from preparation to data quality control, encompassing study design and downstream analysis.

Importance of the G4X Program
This recent accolade builds on the STU's role as an early access site for the G4X Early Access Program, which has recently concluded its successful run across numerous prestigious institutions. The G4X system was commercially launched in the U.S. just last month, marking a pivotal moment for biomedical research.

Dr. Ioannis Vlachos, the Director of the STU and an Associate Professor at BIDMC and Harvard Medical School, expressed enthusiasm regarding this recognition. He highlighted the necessity for solutions that address financial constraints and limited throughput in spatial tissue profiling. The capabilities of the G4X™ system will enable greater flexibility in conducting a variety of pilot projects and supporting large scale clinical trials. This ensures researchers can concentrate on key scientific questions without the burden of resource limitations.

CEO Insights
Josh Stahl, the CEO of Singular Genomics, underscored the importance of establishing Centers of Excellence with leading facilities like the STU. This expansion enhances access to the G4X system, supporting the high-quality, reproducible adoption of in situ multiomics.

Technological Innovations with G4X™
Launched in February 2026, G4X™ represents an innovative leap in multiomics technology. It provides integrated in situ analysis of up to 1,000 RNA target sequences and 18 protein targets simultaneously, on as many as 128 formalin-fixed, paraffin-embedded (FFPE) samples per run. This multifaceted approach delivers vital insights at subcellular resolution and dramatically reduces costs per sample for researchers.

The Future Ahead
The STU at BIDMC is dedicated to providing comprehensive spatial and single-cell capabilities, encompassing everything from tissue sampling to data analysis. With its designation as a G4X Center of Excellence, it stands to enhance its services to scientists at BIDMC, DF/HCC, and throughout the wider research community.

Conclusion
By partnering those on the cutting edge of spatial sequencing, Singular Genomics and the STU are set to propel scientific advancements across various fields of medicine and biology. This initiative is not just about advancing technology, but fundamentally about supporting researchers with the tools they need to uncover important clinical and translational insights.